Human Platelet Lysate Extracellular Vesicles for Scalable Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for using extracellular vesicles (EVs) in therapeutic applications are complex, expensive, and rely on stem cell cultures that are not easily accessible, limiting their large-scale manufacturing and clinical use, while the therapeutic potential of human platelet lysate-derived EVs (hPLEVs) has not been fully explored.
Innovation Solution
Utilize human platelet lysate (hPL) enriched for hPLEVs as a pharmaceutical, diagnostic, or cosmetic preparation to treat inflammatory, immune, neurodegenerative, cardiovascular, dermatologic, orthopedic, and oncologic diseases, as well as for tissue regeneration and cosmetic applications, leveraging the accessibility and lower cost of platelet sources compared to stem cell-derived EVs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell-derived extracellular vesicles are used for therapeutic applications, then therapeutic potential is achieved, but manufacturing complexity and cost increase significantly
Solution Approach 1:
The patent extracts and isolates extracellular vesicles from human platelet lysate, separating them from the complex stem cell culture system. This extraction approach allows therapeutic applications to be achieved using a simpler, more accessible source material (platelets) instead of requiring complex stem cell-derived EVs, thereby reducing manufacturing complexity while maintaining therapeutic potential.
Solution Approach 2:
The patent utilizes human platelet lysate as a readily available, inexpensive source compared to stem cell cultures. Platelets can be obtained from standard blood donations and have a relatively short shelf life, which actually benefits the therapeutic application by ensuring freshness and reducing the need for complex long-term storage and culture systems. This approach replaces expensive, complex stem cell systems with a more economical, disposable-like source.
2Reliability
If stem cell cultures are used to produce extracellular vesicles, then therapeutic efficacy is achieved, but accessibility and scalability are limited
Solution Approach 1:
The patent demonstrates that human platelet lysate can serve as a universal source for extracellular vesicles with therapeutic efficacy. Platelets are a common blood component that can be obtained from any blood donor, making the source universally accessible. This multi-functional use of platelet lysate (providing both growth factors and EVs) replaces the need for specialized stem cell cultures, significantly improving accessibility and scalability for therapeutic production.
Solution Approach 2:
The patent changes the source parameter from stem cells to platelet lysate, fundamentally altering the availability and scalability characteristics. Platelet lysate can be produced from standard blood donations without requiring specialized culture facilities, thereby changing the manufacturing parameters to be more accessible and scalable while maintaining therapeutic efficacy through the preservation of EVs and growth factors.
3Ease of manufacture
If human platelet lysate is used as a supplement, then cost is reduced and accessibility is improved, but therapeutic potential was previously underexplored
Solution Approach 1:
The patent performs preliminary characterization and validation of human platelet lysate-derived extracellular vesicles to establish their therapeutic potential before widespread application. By conducting these preliminary studies to confirm efficacy and safety profiles, the patent enables the transition from a cost-effective but unproven source to a reliable therapeutic option, thereby resolving the contradiction between cost/accessibility and proven therapeutic potential.
Data Source
AI summary
The present invention is related to human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles and their use in medicine, particularly for the prevention and/or treatment of inflammatory driven diseases, neurodegenerative diseases, immune/autoimmune diseases, cardiovascular diseases, dermatologic diseases, orthopedic diseases, tissue regenerative medicine, oncologic diseases, infectious diseases, transplant rejections, stroke, ischemia or Graft-versus-Host Disease. The present invention is further related to a method of manufacture of a pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation comprising the step of adding human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles to the pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation.